You are here: Industry Insights > COVID-19

News List

EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine worldpharmanews
December 02, 2020
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 mRNA vaccine by Moderna Biotech Spain, S.L.
EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2 worldpharmanews
December 02, 2020
EMA has received an application for conditional marketing authorisation (CMA) for BNT162b2, a COVID?19 mRNA vaccine developed by BioNTech and Pfizer.
FDA grants COVID-19 treatment Fast Track designation europeanpharmaceuticalreview
December 02, 2020
The designation should expedite the development and review of AB201, a recombinant protein therapy being tested in hospitalised COVID-19 patients.
NeoImmuneTech doses first patient in Covid-19 trial pharmaceutical-business-review
December 02, 2020
NeoImmuneTech has dosed the first patient in its phase 1 study designed to assess NT-I7 (efineptakin alfa) in adult patients with mild Covid-19.
ELITechGroup MDx Announces EUA Submission for SARS-CoV-2 Plus ELITe MGB Assay americanpharmaceuticalreview
December 02, 2020
ELITechGroup MDx has submitted the SARS-CoV-2 Plus ELITe MGB? Assay to the U.S. Food & Drug Association's (FDA's) for Emergency Use Authorization (EUA), following the Molecular Diagnostic Template for Commercial Manufacturers.
Ampion Study Advances to 3rd Group of COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
December 02, 2020
Ampio Pharmaceuticals announced the third group in the Phase I inhaled Ampion? clinical study is being treated following clearance by the Safety Monitoring Committee (SMC) who found Ampion to be safe and well-tolerated after reviewing the results from ...
Recipharm Inks Covid-19 Vax Pact with Moderna contractpharma
December 02, 2020
Signs of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273).
Colchicine added to UK’s COVID-19 ‘RECOVERY’ trial pharmatimes
December 01, 2020
Commonly used anti-inflammatory drug colchicine is set to be investigated in the UK’s RECOVERY trial, which is testing treatments for patients hospitalised with COVID-19.
Researchers warn pandemic could delay cancer advances ‘by almost a year’ pharmatimes
December 01, 2020
A new survey has detailed cancer researchers’ concerns that advances for patients could be delayed by nearly 18 months due to the impact of the COVID-19 pandemic.
COVID-19 could cause long-term lung damage, research finds pharmatimes
December 01, 2020
Research conducted at Oxford University suggests that COVID-19 may be causing lung-damage in patients that can be detected over three months after the initial infection.